Table 1.
Marker | Clinical Correlation | Reference |
---|---|---|
HLA-DR | Decreased with CsA and Tofacitinab treatment | 45,56 |
MMP-9 | Symptom severity, corneal fluorescein staining, conjunctival lissamine green staining | 31 |
Tear EGF | Ocular surface rose Bengal staining, corneal fluorescein staining, conjunctival lissamine green staining | 40,65 |
Tear IL-6 | Ocular surface rose bengal staining, corneal fluorescein staining, conjunctival lissamine green staining | 40,65 |
Tear IL-8, MIP-1α, IL-1β | Corneal fluorescein staining, conjunctival lissamine green staining, | 40 |
Tear CXCL9 (I-TAC) | Basal tear secretion, keratoepitheliopathy, goblet cell density | 66 |
Tear proteins S100A8 and A9 Lactoferrin Lipocalin |
In subjects with MGD Grittiness, transient blur Eye pain and tearing Tearing, lid heaviness | 43 |
MUC16 mRNA MUC16 cellular MUC5AC tears |
Tear meniscus Lissamine green staining, Dry eye symptom questionnaire Lissamine green staining |
67 |
Correlation coefficient ≥ 0.35
HLA-DR= human leukocyte antigen DR, MMP-9=matrix metalloproteinase 9, EGF=epidermal growth factor, IL-6=interleukin 6, IL-1= interleukin 1, MIP-1α= macrophage inflammatory protein 1, MGD: meibomian gland disease, CXCL9= chemokine (C-X-C motif) ligand 9, MUC= mucin